| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 02/28/2002 | US20020026037 For diagnosing and treating disorders related to this novel human protein such as disorders related to the vascular and lymphatic systems |
| 02/28/2002 | US20020025941 Combination product intended for carrying out a cytotoxic treatment, in particular an antitumour treatment, in a mammal |
| 02/28/2002 | US20020025939 Chorionic gonadortropin dna vaccines and methods |
| 02/28/2002 | US20020025920 Novel lipid complexes for transferring at least one therapeutically active substance, in particular a polynucleotide, into a target cell, and use in gene therapy |
| 02/28/2002 | US20020025578 Intensified expression of nucleotide sequences in mammal; administer nucleic acids to mammal, transfect nucleotide sequence using voltage, monitor mammal for gene expression |
| 02/28/2002 | US20020025577 Eukaryotic gene expression cassette and uses thereof |
| 02/28/2002 | US20020025558 Human MAD proteins and uses thereof |
| 02/28/2002 | US20020025557 32447, a novel human acyltransferase and uses thereof |
| 02/28/2002 | US20020025553 Nucleotide sequences which code preferential polypeptide for use diagnosis, prevention and treatment of cancer, ulcers, psoriasis, nervous system, liver, kidney and vision defects; wound healing agents |
| 02/28/2002 | US20020025543 Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
| 02/28/2002 | US20020025522 Compositions comprising genome segments and methods of using the same |
| 02/28/2002 | US20020025516 Nrde |
| 02/28/2002 | US20020025307 Gene therapy, testing |
| 02/28/2002 | US20020025306 Providing a source of a glucoincretin that increases the responsiveness of the cell to glucose |
| 02/28/2002 | US20020025305 Cell-cycle regulatory proteins, and uses related thereto |
| 02/28/2002 | US20020025296 Selecting foreign gene which has been isolated from a cell or virus and which has been transferred into the cells; selecting a labelled compound which will interact selectively with a protein; administering to the cells an effective dose |
| 02/28/2002 | CA2674888A1 Anti-ige vaccines |
| 02/28/2002 | CA2674838A1 Anti-ige vaccines |
| 02/28/2002 | CA2456008A1 Stem cell differentiation |
| 02/28/2002 | CA2420543A1 Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers |
| 02/28/2002 | CA2420499A1 Methods of treatment or prevention of autoimmune diseases with cpg-containing polynucleotide |
| 02/28/2002 | CA2420482A1 Progression suppressed gene 13 (psgen 13) and uses thereof |
| 02/28/2002 | CA2420261A1 Genes and proteins, and their uses |
| 02/28/2002 | CA2420193A1 Compositions and methods for the diagnosis and treatment of tumor |
| 02/28/2002 | CA2420134A1 12 human secreted proteins |
| 02/28/2002 | CA2420087A1 Cripto tumour polypeptide |
| 02/28/2002 | CA2419915A1 New sequences |
| 02/28/2002 | CA2419840A1 Treatment of hyperproliferative diseases |
| 02/28/2002 | CA2419454A1 Regulator gene and system useful for the diagnosis and therapy of osteoporosis |
| 02/28/2002 | CA2419306A1 23 human secreted proteins |
| 02/28/2002 | CA2418680A1 11 human secreted proteins |
| 02/28/2002 | CA2418676A1 21 human secreted proteins |
| 02/28/2002 | CA2418474A1 21 human secreted proteins |
| 02/28/2002 | CA2418461A1 Method and compositions for promoting osteogenesis |
| 02/28/2002 | CA2388061A1 Diagnosis and treatment of cardiovascular conditions |
| 02/28/2002 | CA2356124A1 Anti-ige vaccines |
| 02/27/2002 | EP1182259A1 Pyruvate:NADP+ oxidoreductase and uses thereof |
| 02/27/2002 | EP1182255A1 Genes involved in immune related responses observed with asthma |
| 02/27/2002 | EP1182208A2 Composition for DNA transfection |
| 02/27/2002 | EP1181937A2 Novel vaccine adjuvant and vaccine |
| 02/27/2002 | EP1181390A1 27 human secreted proteins |
| 02/27/2002 | EP1181385A2 Modulation of gene expression in gastrointestinal inflammation |
| 02/27/2002 | EP1181382A2 Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration |
| 02/27/2002 | EP1181381A2 Organ, tissue and cell-specific immuno-therapeutic for chronic viral infections and inflammatory, degenerative and proliferative diseases, in particular of the liver, and for cancer, based on a recombinant parapox virus |
| 02/27/2002 | EP1181376A2 Gene construct for prodrug activation encoding a heterologous, glycosylphophatidylinositol-modified carboxypeptidase g2 and a cell surface targeting signal peptide |
| 02/27/2002 | EP1181369A1 Four-helical bundle protein zsig81 |
| 02/27/2002 | EP1181367A2 Polynucleotides and membrane-bound polypeptides encoded thereby |
| 02/27/2002 | EP1181362A1 Methods and reagents for inhibiting angiogenesis |
| 02/27/2002 | EP1181358A2 Methods and materials for generating sh3 domains with tailored binding properties |
| 02/27/2002 | EP1181352A1 Versican and epithelial-mesenchymal interaction |
| 02/27/2002 | EP1181320A2 Somatic transgene immunization and related methods |
| 02/27/2002 | EP1181318A2 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules |
| 02/27/2002 | EP1181317A1 An integrin heterodimer and an alpha subunit thereof |
| 02/27/2002 | EP1181316A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS |
| 02/27/2002 | EP1181305A1 Methods of modulating activity of prokaryotic ribosomes |
| 02/27/2002 | EP1181304A1 Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin |
| 02/27/2002 | EP1181303A1 50 human secreted proteins |
| 02/27/2002 | EP1181057A1 Noninvasive genetic immunization, expression products therefrom, and uses thereof |
| 02/27/2002 | EP1181056A1 Lim mineralization protein splice variants |
| 02/27/2002 | EP1181042A1 Neurotrophic factors in the treatment of peripheral nerve dysfunction of pelvic area |
| 02/27/2002 | EP1181037A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 02/27/2002 | EP1181031A1 Novel antiangiogenic peptides |
| 02/27/2002 | EP1180932A1 Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| 02/27/2002 | EP0939623B1 Oral delayed immediate release formulation and method of preparation therefor |
| 02/27/2002 | EP0827545B1 Retroviral vectors |
| 02/27/2002 | CN1337884A Gene therapy for cardiomyopathy |
| 02/27/2002 | CN1079833C Recombinant P53 adenovirus method and compositions |
| 02/26/2002 | US6350858 A polypeptide involved in controlling phosphate retention; diagnosis and therapy for chronic kidney failure, end stage kidney disease, uremic bone disease, and cancer |
| 02/26/2002 | US6350857 Fifty-four homologue (ffh) from streptococcus pneumoniae |
| 02/26/2002 | US6350730 OB polypeptides and modified forms as modulators of body weight |
| 02/26/2002 | US6350600 A polypeptide encoding transfer rna-methyl transferase; screening antibiotics, therapy for streptococcus pneumoniae infections; drug development |
| 02/26/2002 | US6350598 MurD |
| 02/26/2002 | US6350575 Helper viruses for the preparation of recombinant viral vectors |
| 02/26/2002 | US6350446 Polypeptides with amino acid sequences for kidney failure |
| 02/26/2002 | US6350445 Method of treating cancer with a tumor cell line having modified cytokine expression |
| 02/26/2002 | US6350444 Gene therapy for pulmonary edema using adenovirus vectors encoding Na,K-ATPase |
| 02/26/2002 | CA2072484C Use of nadh or nadph against cancer and aids |
| 02/21/2002 | WO2002014527A2 Gp64-null baculoviruses pseudotyped with heterologous envelope proteins |
| 02/21/2002 | WO2002014526A2 Replication competent aav helper functions |
| 02/21/2002 | WO2002014522A1 Pyruvate:nadp+ oxidoreductase and uses thereof |
| 02/21/2002 | WO2002014513A1 Use of polypeptide |
| 02/21/2002 | WO2002014512A1 Novel proteins and dnas thereof |
| 02/21/2002 | WO2002014511A2 Regulation of human p2y1-like g protein-coupled receptor |
| 02/21/2002 | WO2002014504A1 Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same |
| 02/21/2002 | WO2002014500A2 Human genes and gene expression products |
| 02/21/2002 | WO2002014487A2 Adeno-associated virus-mediated delivery of angiogenic factors |
| 02/21/2002 | WO2002014485A2 Kallikrein gene |
| 02/21/2002 | WO2002014368A2 Proteins and nucleic acids encoding the same |
| 02/21/2002 | WO2002014367A1 Chimeric human-type vascular endothelial cell growth factor |
| 02/21/2002 | WO2002014366A2 Genes involved in immune related responses observed with asthma |
| 02/21/2002 | WO2002014362A2 A hepatitis c virus non-structural ns3/4a fusion gene |
| 02/21/2002 | WO2002014357A2 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage |
| 02/21/2002 | WO2002014352A2 Therapeutic compounds for ovarian cancer |
| 02/21/2002 | WO2002014348A2 Glycoproteins and methods of use thereof |
| 02/21/2002 | WO2002013882A1 Implants with a phosphazene-containing coating |
| 02/21/2002 | WO2002013867A2 Augmented cognitive training |
| 02/21/2002 | WO2002013855A2 Vaccines containing ribavirin and methods of use thereof |
| 02/21/2002 | WO2002013845A2 Inflammation related g-protein coupled receptor |
| 02/21/2002 | WO2002013758A2 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 02/21/2002 | WO2001083722A3 Enzymes useful for treating and methods for treating mps-vi and cells lines for producing such enzymes recombinantly |